Findings from a feasibility study of estradiol for hypogonadal women with cystic fibrosis-related bone disease

Malinda Wu, Rabindra Tirouvanziam, Neha Arora, Vin Tangpricha, Malinda Wu, Rabindra Tirouvanziam, Neha Arora, Vin Tangpricha

Abstract

Background: Advancements in therapies for patients with cystic fibrosis (CF) have decreased mortality, leading to increased prevalence of chronic complications including bone disease. CF-related bone disease (CFBD) is characterized by low bone mineral density (BMD) and fragility fractures. Estrogen deficiency increases bone resorption, resulting in decreased BMD that can be restored with estrogen replacement. Current CF guidelines recommend treating female hypogonadal patients with CFBD with estrogen replacement, but no prospective study has investigated the effects of estrogen supplementation on CFBD. Estrogen is known to modulate inflammatory markers and autoimmune diseases. We proposed to test the hypothesis that estrogen status plays a critical role in optimizing bone health, modulating inflammation, preserving lung function, and maximizing quality of life in premenopausal women with CF.

Methods: We planned a randomized, placebo-controlled, investigator- and patient-blinded, pilot trial with two parallel arms. Eligible subjects were women with CF 18-50 years old with hypogonadism and low BMD who were not taking systemic glucocorticoids, had not had a prior transplant, and did not have contraindications to oral estradiol. Subjects would be block randomized to receive oral estradiol or placebo for 6 months. The primary outcome was feasibility metrics. Secondary outcomes included relative changes in estradiol, bone turnover markers, lung function, inflammatory markers, and quality of life metrics. The study was funded through departmental funds.

Results: Of 233 subjects screened, 86 subjects were women with CF 18-50 years old and none were eligible for participation. Most subjects were excluded due to absent DXA report (24%), normal BMD (22%), or use of systemic estrogen (16%). Due to difficulty recruiting the planned 52 subjects, the trial was closed for recruitment and no subjects were randomized.

Conclusion: This study was designed to investigate the feasibility of a safety and efficacy trial of estrogen therapy for women with CF. Unfortunately, due to eligibility criteria, the study was unable to recruit subjects. This feasibility study highlights the need for improved BMD screening in young women with CF. Future study designs may require the incorporation of a screening DXA as part of subject recruitment.

Trial registration: The study was registered on ClinicalTrials.gov ( NCT03724955 ).

Keywords: Cystic fibrosis; Cystic fibrosis-related bone disease; Estradiol; Estrogen; Hypogonadism; Osteoporosis; Pre-menopausal; Young adult.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2021. The Author(s).

Figures

Fig. 1
Fig. 1
Overview of study design
Fig. 2
Fig. 2
Consort flow diagram

References

    1. Cystic Fibrosis Foundation Patient Registry . Annual Data Report. Bethesda: Cystic Fibrosis Foundation; 2017. p. 2018.
    1. Sermet-Gaudelus I, Bianchi ML, Garabedian M, Aris RM, Morton A, Hardin DS, et al. European cystic fibrosis bone mineralisation guidelines. J Cyst Fibros. 2011;10(Suppl 2):S16–S23. doi: 10.1016/S1569-1993(11)60004-0.
    1. Aris RM, Merkel PA, Bachrach LK, Borowitz DS, Boyle MP, Elkin SL, Guise TA, Hardin DS, Haworth CS, Holick MF, Joseph PM, O’Brien K, Tullis E, Watts NB, White TB. Guide to bone health and disease in cystic fibrosis. J Clin Endocrinol Metab. 2005;90(3):1888–1896. doi: 10.1210/jc.2004-1629.
    1. Anabtawi A, Le T, Putman M, Tangpricha V, Bianchi ML. Cystic fibrosis bone disease: Pathophysiology, assessment and prognostic implications. J Cyst Fibros. 2019;18:S48–S55. doi: 10.1016/j.jcf.2019.08.018.
    1. Shead EF, Haworth CS, Condliffe AM, McKeon DJ, Scott MA, Compston JE. Cystic fibrosis transmembrane conductance regulator (CFTR) is expressed in human bone. Thorax. 2007;62(7):650–651. doi: 10.1136/thx.2006.075887.
    1. Putman MS, Anabtawi A, Le T, Tangpricha V, Sermet-Gaudelus I. Cystic fibrosis bone disease treatment: Current knowledge and future directions. J Cyst Fibros. 2019;18:S56–S65. doi: 10.1016/j.jcf.2019.08.017.
    1. Cauley JA, Danielson ME, Greendale GA, Finkelstein JS, Chang YF, Lo JC, et al. Bone resorption and fracture across the menopausal transition: the Study of Women's Health Across the Nation. Menopause. 2012;19(11):1200–1207. doi: 10.1097/gme.0b013e31825ae17e.
    1. Vasikaran S, Eastell R, Bruyere O, Foldes AJ, Garnero P, Griesmacher A, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int. 2011;22(2):391–420. doi: 10.1007/s00198-010-1501-1.
    1. Szulc P, Naylor K, Hoyle NR, Eastell R, Leary ET, for the National Bone Health Alliance Bone Turnover Marker P Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability. Osteoporos Int. 2017;28(9):2541–2556. doi: 10.1007/s00198-017-4082-4.
    1. Ionescu AA, Nixon LS, Evans WD, Stone MD, Lewis-Jenkins V, Chatham K, et al. Bone density, body composition, and inflammatory status in cystic fibrosis. Am J Respir Crit Care Med. 2000;162(3 Pt 1):789–794. doi: 10.1164/ajrccm.162.3.9910118.
    1. Kazmerski TM, Sawicki GS, Miller E, Jones KA, Abebe KZ, Tuchman LK, Ladores S, Rubenstein RC, Sagel SD, Weiner DJ, Pilewski JM, Orenstein DM, Borrero S. Sexual and reproductive health behaviors and experiences reported by young women with cystic fibrosis. J Cyst Fibros. 2018;17(1):57–63. doi: 10.1016/j.jcf.2017.07.017.
    1. Roe AH, Traxler S, Schreiber CA. Contraception in women with cystic fibrosis: a systematic review of the literature. Contraception. 2016;93(1):3–10. doi: 10.1016/j.contraception.2015.07.007.
    1. Kernan NG, Alton EW, Cullinan P, Griesenbach U, Bilton D. Oral contraceptives do not appear to affect cystic fibrosis disease severity. Eur Respir J. 2013;41(1):67–73. doi: 10.1183/09031936.00018712.
    1. Chotirmall SH, Smith SG, Gunaratnam C, Cosgrove S, Dimitrov BD, O'Neill SJ, Harvey BJ, Greene CM, McElvaney NG. Effect of estrogen on pseudomonas mucoidy and exacerbations in cystic fibrosis. N Engl J Med. 2012;366(21):1978–1986. doi: 10.1056/NEJMoa1106126.
    1. Fitzpatrick SB, Stokes DC, Rosenstein BJ, Terry P, Hubbard VS. Use of Oral Contraceptives in Women with Cystic Fibrosis. Chest. 1984;86(6):863–867. doi: 10.1378/chest.86.6.863.
    1. Tirouvanziam R, Gernez Y, Conrad CK, Moss RB, Schrijver I, Dunn CE, Davies ZA, Herzenberg LA, Herzenberg LA. Profound functional and signaling changes in viable inflammatory neutrophils homing to cystic fibrosis airways. Proc Natl Acad Sci U S A. 2008;105(11):4335–4339. doi: 10.1073/pnas.0712386105.
    1. Thobani A, Alvarez JA, Blair S, Jackson K, Gottlieb ER, Walker S, et al. Higher Mobility Scores in Patients with Cystic Fibrosis Are Associated with Better Lung Function. Pulmonary Med. 2015;2015:423219. doi: 10.1155/2015/423219.
    1. Gottlieb ER, Smith EC, Wolfenden LL, Allman RM, Tangpricha V. Life-space mobility is associated with frequency of hospitalization in adults with cystic fibrosis. Clin Respir J. 2011;5(4):245–251. doi: 10.1111/j.1752-699X.2010.00225.x.
    1. Reiter EO, Stern RC, Root AW. The reproductive endocrine system in cystic fibrosis: I. basal gonadotropin and sex steroid levels. Am J Dis Child. 1981;135(5):422–426. doi: 10.1001/archpedi.1981.02130290020009.
    1. Rousset Jablonski C, Reynaud Q, Perceval M, Nove-Josserand R, Durupt S, Lega JC, Durieu I. Contraceptive practices and cervical screening in women with cystic fibrosis. Hum Reprod. 2015;30(11):2547–2551. doi: 10.1093/humrep/dev217.
    1. Korzeniewska A, Grzelewski T, Jerzynska J, Majak P, Soloniewicz A, Stelmach W, et al. Sexual and reproductive health knowledge in cystic fibrosis female patients and their parents. J Sex Med. 2009;6(3):770–776. doi: 10.1111/j.1743-6109.2008.01049.x.
    1. Plant BJ, Goss CH, Tonelli MR, McDonald G, Black RA, Aitken ML. Contraceptive practices in women with cystic fibrosis. J Cyst Fibros. 2008;7(5):412–4. 10.1016/j.jcf.2008.03.001.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel